한글목차

CNM-Au8은 에너지 생산과 이용을 증가시켜 신경세포의 건강과 기능을 회복시키기 위해 개발된 금 나노 결정의 경구용 현탁액으로, CNM-Au8의 촉매 활성 나노 결정은 중요한 세포 에너지 생산 반응을 촉진하고 질병 관련 스트레스 요인에 대한 신경세포 및 신경교세포의 회복력을 향상시켜 신경 보호 및 재수초화를 가능하게 합니다. 신경세포와 신경교세포의 회복력을 향상시켜 신경 보호 및 재수초화를 가능하게 합니다.

CNM-Au8은 파킨슨병 환자를 대상으로 한 임상 2상 시험을 완료했으며, CNM-Au8이 신경 퇴행성 질환 치료에서 의미 있는 신경 기능 개선을 촉진할 수 있는 가능성을 뒷받침하는 데이터를 확보했습니다. 회사는 파킨슨병 환자에서 CNM-Au8의 질병 진행을 늦추거나 예방하는 효과를 조사하기 위해 자본의 가용성에 따라 또 다른 임상 2상 시험을 실시할 계획입니다.

앞으로 몇 년동안 파킨슨병 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 증가로 인해 변화할 것입니다. 각 회사는 질병을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, CNM-Au8의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 파킨슨병에 대한 다른 신흥 제품들은 CNM-Au8과 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 7개국의 파킨슨병 치료제 CNM-Au8 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 파킨슨병에서의 CNM-Au8 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 CNM-Au8 시장 평가

• 파킨슨병용 CNM-Au8 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 파킨슨병 치료제 CNM-Au8 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"CNM-Au8 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about CNM-Au8 for Parkinson's disease in the seven major markets. A detailed picture of the CNM-Au8 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the CNM-Au8 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CNM-Au8 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy-producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors.

CNM-Au8 has completed a Phase II trial for Parkinson's disease, data supported the potential of CNM-Au8 to drive meaningful neurological functional improvements in the treatment of neurodegenerative disorders. The company is planning to conduct another Phase II trial subject to capital availability to investigate the effects of CNM-Au8 on slowing or preventing disease progression in Parkinson's disease patients.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the CNM-Au8 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on CNM-Au8 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CNM-Au8 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CNM-Au8.
• The report contains forecasted sales of CNM-Au8 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for CNM-Au8 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CNM-Au8 Analytical Perspective by DelveInsight

• In-depth CNM-Au8 Market Assessment

This report provides a detailed market assessment of CNM-Au8 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• CNM-Au8 Clinical Assessment

The report provides the clinical trials information of CNM-Au8 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CNM-Au8 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to CNM-Au8 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CNM-Au8 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of CNM-Au8 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the CNM-Au8 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of CNM-Au8?
• What is the clinical trial status of the study related to CNM-Au8 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the CNM-Au8 development?
• What are the key designations that have been granted to CNM-Au8 for Parkinson's disease?
• What is the forecasted market scenario of CNM-Au8 for Parkinson's disease?
• What are the forecasted sales of CNM-Au8 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to CNM-Au8 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. CNM-Au8 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. CNM-Au8 Market Assessment

• 5.1. Market Outlook of CNM-Au8 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of CNM-Au8 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of CNM-Au8 in the United States for Parkinson's disease
  • 5.3.2. Market Size of CNM-Au8 in Germany for Parkinson's disease
  • 5.3.3. Market Size of CNM-Au8 in France for Parkinson's disease
  • 5.3.4. Market Size of CNM-Au8 in Italy for Parkinson's disease
  • 5.3.5. Market Size of CNM-Au8 in Spain for Parkinson's disease
  • 5.3.6. Market Size of CNM-Au8 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of CNM-Au8 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options